We are live on
!
Find out more
CCM
Consonance Capital Management Portfolio holdings
AUM
$7.28M
1-Year Est. Return
43.59%
This Fund
S&P 500
This Quarter
Est. Return
-31.81%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$7.28M
AUM Growth
-$16.4M
(-69%)
Cap. Flow
-$13M
Cap. Flow
% of AUM
-178.53%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
–
Reduced
–
Closed
5
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SLN
Silence Therapeutics
SLN
|
+$7.52M |
| 2 |
Compass Therapeutics
CMPX
|
+$4.22M |
| 3 |
United Therapeutics
UTHR
|
+$706K |
| 4 |
Globus Medical
GMED
|
+$303K |
| 5 |
Tandem Diabetes Care
TNDM
|
+$254K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.05% |
No holdings matched the selected filter criteria.
Similar funds
GPC
BPM
TVPI
DCI
TPMI
TP
SCG
CVGI
Consonance Capital Management's Q3 2022 Portfolio in Review
As of Q3 2022, Consonance Capital Management held 7 positions worth $7.28M, down 69% from $23.7M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Consonance Capital Management withdrew a net $13M in Q3 2022, closing 5 positions. Its most notable exit was Silence Therapeutics, an estimated $7.52M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 99% a quarter earlier.
- Consonance Capital Management fully exited Silence Therapeutics in Q3 2022, selling an estimated $7.52M.
- Consonance Capital Management's ten largest holdings make up 100% of its $7.28M portfolio in Q3 2022.
- Consonance Capital Management opened 0 new positions and closed 5 in Q3 2022.
- Consonance Capital Management's portfolio value fell 69% quarter-over-quarter to $7.28M.
Based on Consonance Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.